Rein Therapeutics Inc(RNTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.57 | Insider Own | 8.49% | Shs Outstand | 86.3M | Perf Week | -38.98% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | -5.19% | Insider Trans | 0.65% | Shs Float | 79.0M | Perf Month | -44.07% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.1 | Inst Own | 49.18% | Short Float | 0.9% | Perf Quarter | -57.89% |
| Income | -0.05B | P/S | - | EPS this Y | 80.36% | Inst Trans | 48.33% | Short Ratio | 1.15 | Perf Half Y | -67.29% |
| Sales | 0.00B | P/B | 3.74 | EPS next 5Y | 35.74% | ROA | -87.89% | Short Interest | 0.71M | Perf YTD | -70.96% |
| Book/sh | 0.09 | P/C | 0.82 | EPS past 3/5Y | 31.21% 30.56% | ROE | -100.48% | 52W High | -83.96% ($2.10) | Perf Year | -75.59% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -94.21% | 52W Low | 18.46% ($0.28) | Perf 3Y | -82.17% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 40.47% | Gross Margin | - | Volatility(W/M) | 28.22% 15.39% | Perf 5Y | -97.57% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.57 | EPS Q/Q | 70.38% | Profit Margin | - | RSI (14) | 24.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.57 | Sales Q/Q | - | SMA20 | -40.54% ($0.57) | Beta | 1.61 | Target Price | $6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/11/16 | SMA50 | -49.33% ($0.67) | Rel Volume | 1.09 | Prev Close | $0.37 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 40% - | SMA200 | -65.61% ($0.99) | Avg Volume(3M) | 0.61M | Price | $0.34 |
| IPO | 2017/6/29 | Option/Short | No/Yes | Trades | 596 | Volume | 668,753 | Change | -8.38% |
A clinical-stage biopharmaceutical company developing novel drug candidates targeting rare lung diseases and fibrotic conditions. Headquartered in the United States, it is classified as a micro-cap biotech operating with a research-and-development focus, with no commercialized products yet. Pipeline progress serves as the central variable driving the company's valuation.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded about as much as usual. That is 109% of its average volume.
RNTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +80.4% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.6%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 49.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #439 of 598 in the industry
Based on market cap of $29M.
FAQ
RNTX belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of RNTX is approximately $29M, ranking 5,003 within its sector.
RNTX has recorded a 52-week high of $2.10 and a low of $0.28.